SecBot SecBot

RKDA

Arcadia Biosciences, Inc.
Nasdaq· Crude Petroleum & Natural Gas· Inc. DE· CIK 0001469443 Biotech & Drug Discovery
$0.1620 +0.00 (+0.00%)
Oct 23 4:00 PM ET · prev $0.1620
Market cap
$389.8K
Nano cap
1 year
−96.0%
from $4.10 · Oct 24
30 days
−48.7%
from $0.3160
52-week range
$0.1450–4.10
−96% from high · low Oct 19
Avg volume 20D
4.39M
Oct 14 spike 33.84M
Short interest
88.8K
≈3.7% of shares · +824.0%
Days to cover
1.0
at average volume
Insider net
$0
no open-market trades · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
9
analyzed by SecBot
SecBot read MIXED 2 reports · 90 days
Balance 0 bearish · 0 bullish · 2 neutral oldest → newest, height = score
Avg score ·High conf. 1/2 ·Next Earnings date, Nov 5, 2026
Strongest NEUTRAL MJL Manager LLC (the general partner of Capuchin Capital Fund LP) and its control person Michael Liu have…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • InstitutionsMIXED

    Q2 2026: 0 added (0 new), 2 trimmed or exited.

  • Short sellersBUILDING

    Short interest +824.0% to 88.8K shares. 1.0 days to cover, ≈3.7% of shares.

  • TrendDOWNTREND

    56% below its 50-day average. New closing low $0.1450 on Oct 19.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
GEODE CAPITAL MANAGEMENT, LLCTRIM16,135$11.0K
UBS Group AGNEAR_EXIT35$24.00
GEODE CAPITAL MANAGEMENT, LLCDOUBLED31,743$43.8K
UBS Group AGADD807$1.1K
UBS Group AGTRIM565$1.1K
MORGAN STANLEYNEAR_EXIT2$4.00
CITIGROUP INCNEAR_EXIT1$2.00
Pacer Advisors, Inc.TRIM487$36.1K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action Aug 2024
Recent actions
DateFirmActionRating
Aug 21, 2024HC Wainwright & Co.
REITERATE
REITERATEBuy
May 23, 2024HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Apr 5, 2024HC Wainwright & Co.
REITERATE
REITERATEBuy
Aug 28, 2023HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Jul 24, 2023HC Wainwright & Co.
REITERATE
REITERATEBuy
Jun 5, 2023HC Wainwright & Co.
MAINTAIN
MAINTAINBuy

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
Sep 10, 2026
Yoder Amy
Director
AWARD10,000 sh
Sep 10, 2026
Murray Lilian Shackelford
Director
AWARD10,000 sh
Sep 10, 2026
Comcowich Kevin
Director
AWARD23,000 sh
Sep 10, 2026
WALLER GREGORY D
Director
AWARD10,000 sh

Earnings setup

Estimates

Revision history: 🔒 Fresh data — subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data — subscribers only
Next Q🔒 Fresh data — subscribers only
Current FY🔒 Fresh data — subscribers only
Next FY🔒 Fresh data — subscribers only

Short side

FINRA· Sep 30, 2026
88,752
shares short
+824.0%
vs prior settlement
1.0
days to cover
≈3.7%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 30, 2026 SEC
MJL Manager LLC (the general partner of Capuchin Capital Fund LP) and its control person Michael Liu have filed a…
SC 13G — Impact 4/10
Sep 16, 2026 SEC
Arcadia Biosciences filed an 8-K covering Item 5.02 (director/officer changes), Item 5.07 (shareholder vote results)…
8-K — Impact 3/10
Sep 10, 2026 Insider
Yoder Amy was granted 10,000 shares
Director
Sep 10, 2026 Insider
Murray Lilian Shackelford was granted 10,000 shares
Director
Sep 10, 2026 Insider
Comcowich Kevin was granted 23,000 shares
Director
Aug 12, 2026 Listing status
Listing Status: RKDA — Deficient (was Normal)
Arcadia Biosciences, Inc. - Common Stock | Nasdaq Financial Status Indicator N → D
Jul 9, 2026 SEC
Arcadia Biosciences' shelf registration (File No. 333-297072) became effective on July 8, 2026, enabling the resale of…
EFFECT — Impact 6/10
Jun 30, 2026 Inst.
GEODE CAPITAL MANAGEMENT, LLC — TRIM
16,135 shares ($11.0K)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 5, 2026
Earnings date
🔒 Fresh data — subscribers only
Recent
Aug 12, 2026
Listing
Listing Status: RKDA — Deficient (was Normal)
Arcadia Biosciences, Inc. - Common Stock | Nasdaq Financial Status Indicator N → D
Aug 12, 2026
Earnings date
RKDA Q2 2026 Earnings Scheduled — 2026-08-12
Jun 13, 2026
Offering
Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
DALLAS, June 12, 2026 (GLOBE NEWSWIRE) -- Arcadia Biosciences, Inc . ® (Nasdaq: RKDA), a producer and marketer of innovative wellness products…
Jun 12, 2026
Offering
Arcadia Biosciences (RKDA) Announces $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
DALLAS, June 11, 2026 (GLOBE NEWSWIRE) -- Arcadia Biosciences, Inc . ® (Nasdaq: RKDA), a producer and marketer of innovative wellness products…
May 6, 2026
Earnings date
RKDA Q1 2026 Earnings Scheduled — 2026-05-06

SecBot reports

9 filings · 3 press releases · 0 bullish · 5 bearish · 4 neutral
All RKDA filing & press-release reports (12)